Bentracimab的临床与临床前药代动力学及药效学
本文系统综述了抗血小板药物逆转剂bentracimab的研发项目,聚焦其药效学、药代动力学和安全性特征。Bentracimab是一种中和性单克隆抗体片段,可结合血浆中游离的替格瑞洛及其主要活性代谢物。目前尚无获批的抗血小板药物逆转剂,而bentracimab为替格瑞洛相关出血管理提供了潜在选择。
要点
- Bentracimab可结合游离替格瑞洛及其主要活性代谢物,发挥中和逆转作用。
- 替格瑞洛血浆半衰期为7-9小时,可逆性结合P2Y12受体。
- 阿司匹林和噻吩吡啶类不可逆结合靶点,难以开发特异性逆转剂。
核心结论
- Bentracimab是一种中和性单克隆抗体片段,可结合游离血浆替格瑞洛及其主要活性代谢物。
- 该综述全面总结了bentracimab研发项目的药效学、药代动力学和安全性特征。
研究设计与样本
- 系统综述,汇总bentracimab的临床前与临床研发项目数据。
主要发现
- 替格瑞洛血浆半衰期为7-9小时,可逆性结合P2Y12受体产生强效信号阻断。
- 阿司匹林和噻吩吡啶类(氯吡格雷、普拉格雷)不可逆结合靶点,是开发药物特异性逆转剂的挑战。
- 经皮冠状动脉介入治疗患者中5-15%可能在2年内需要外科手术。
临床怎么用
- Bentracimab可作为替格瑞洛抗血小板作用的逆转候选药物,用于需紧急手术或严重出血的管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antiplatelet agents are among the most frequently used medications in cardiovascular medicine. Although in patients with atherosclerotic disease manifestations, in particular those treated by percutaneous coronary intervention, antiplatelet agents are beneficial for the prevention of ischemic events, they inevitably increase the risk of bleeding. Furthermore, 5-15% of patients treated by percutaneous coronary intervention may need a surgical procedure within 2 years, creating challenges to safe and effective antiplatelet drug management. Importantly, major spontaneous or procedural-related bleedings are associated with increased hospital admission, length, costs, and poor prognosis. Although the effects of other antithrombotic therapies, such as direct oral anticoagulants, can be reversed by approved specific agents, there are no approved reversal agents for any antiplatelet drugs. The fact that many antiplatelet agents, such as aspirin and thienopyridines (i.e., clopidogrel and prasugrel), bind irreversibly to their targets represents a challenge for the development of a drug-specific reversal agent. In contrast, ticagrelor is a non-thienopyridine with a plasma half-life of 7-9 h that reversely binds the P2Y12 receptor producing potent signaling blockage. In 2015, bentracimab (also known as PB2452 or MEDI2452), a neutralizing monoclonal antibody fragment that binds free plasma ticagrelor and its major active metabolite, was identified. This systematic overview provides a comprehensive summary of the drug development program of bentracimab, focusing on its pharmacodynamic, pharmacokinetic, and safety profiles.
引用
- Ortega-Paz L, Giordano S, Franchi F, et al. Clinical and Pre-Clinical Pharmacokinetics and Pharmacodynamics of Bentracimab. Clin Pharmacokinet. 2023. PMID: 37118383. doi:10.1007/s40262-023-01245-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。